Skip to main content

GenOdyssee Hires Three VPs; SRI Hires Calif. State Exec; and others

NEW YORK, Sept. 25 - ActivX Biosciences has promoted Jonathan Burbaum to vice president, advanced technology, from executive director, advanced technology, the company said on Sept. 24.

 

Burbaum will direct development of the company's technologies in high-throughput screening, capillary electrophoresis, and mass spectrometry.

 

Before joining ActivX, Burbaum developed a screening platform for Pharmacopoeia and worked in crystallography and protein expression at Merck.

 

ActivX Biosciences is a proteomics company based in La Jolla, Calif.

 


 

The French firm GenOdyssee said on Sept. 24 it had hired three new vice presidents:

 

David Briscoe joins the firm as vice president of business development. He was most recently commercial director of the British biotech firm Pharmagene, and was previously president of European operations for Incyte.

 

Jean-Marc Giry, who is experienced in high-tech marketing and business development, will be the company's new vice president of strategic planning.

 

Phillippe Remes, who was most recently vice president, Northern Europe for Tyco Healthcare, joins GenOdyssee as vice president of investor relations.

 

GenOdyssee performs genetic analysis and develops therapeutics. It is based in Paris.

 


 

Genome Express, the French functional genomics firm, has appointed Francois Pons as director of business development.

 

He will promote the company's genomics and proteomics platform and develop collaborations and alliances.

 

Pons was previously director of business development and scientific communication at the Centre d'Immunologie Pierre Fabre, where he negotiated partnerships, licensing agreements, and research consortia.

 


 

SRI International hired Joe Raguso as its vice president of strategic partnerships, the research institute said on Sept. 19.

 

Raguso will coordinate partnerships in information technology, biotechnology, and wireless communications.

 

He was previously deputy secretary of the division of science, technology, and innovation in the state of California's trade and innovation agency, where he advised the governor and the state legislature on technology policy. He has also worked with the Defense Advanced Research Projects Agency, and was deputy assistant secretary to the Office of Technology Policy in the Clinton Administration.

 

SRI is an independent R&D institute based in Menlo Park, Calif.

 



Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.